Schering-Plough Shows Off Once-Daily Hep C Drug Narlaprevir At AASLD
This article was originally published in Pharmaceutical Approvals Monthly
BOSTON - Schering-Plough's (now Merck's) next-generation hepatitis C therapy narlaprevir may shape up as a better competitor for the Vertex hepatitis C drug telaprevir than Schering's first generation protease inhibitor boceprevir, if the ritonavir-boosted Phase IIa trial for narlaprevir stays true to the initial results
You may also be interested in...
Is it a trick or a treat? AASLD lifts embargo on all annual meeting data at Halloween press conference.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011